3 'Strong Buy' Growth Stocks to Buy Now, 8/12/2025, According to Analysts
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
One way to identify these stocks is through their past revenue or earnings growth. Today, we have shortlisted stocks whose revenue has grown at a five-year CAGR of more than 10%. Along with this parameter, we have zeroed in on stocks that have received Strong Buy ratings from Wall Street analysts.
Here are this week's stocks:
Insulet (PODD) – Insulet provides insulin delivery systems for people with diabetes. PODD stock's average price target of $359.44 implies a 16.63% upside potential from the current levels. The company's revenue has grown at a five-year CAGR of over 18%.
Intuit (INTU) – This financial software company is known for products such as TurboTax, QuickBooks, and Credit Karma that help individuals and businesses manage their finances. INTU stock's average price target of $845.45 implies an upside potential of 18.5%. Its revenue increased at a CAGR of 16.23% in the past five years.
ARM Holdings (ARM) – This semiconductor and software design company creates energy-efficient processor architectures used in mobile devices. ARM stock has a price forecast of $170.76, which implies a 19.85% upside potential. The company's revenues have witnessed a five-year CAGR of 14.59%.
What Is TipRanks' Smart Growth Newsletter?
TipRanks' Smart Growth Newsletter provides top growth investment ideas on a weekly basis, based on TipRanks' data and analysis. The newsletter includes macroeconomic, market-wide, and company-specific analysis to help investors understand the trends that may influence their growth investments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
43 minutes ago
- Business Insider
Why OpenAI's AI Crown Isn't Safe with GPT-5
OpenAI's much-anticipated GPT-5 has seen a bumpy debut, as many users have taken to social media to share examples of the chatbot making mistakes on simple math problems or misdrawing maps of North America. Others disliked what they saw as a colder, less personable tone compared to older versions, which the Microsoft-backed (MSFT) AI firm had previously removed. Furthermore, the addition of a 200-question-per-week limit upset loyal users. As a result, what was initially expected to crown OpenAI as the king of AI instead led to doubt. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In response, CEO Sam Altman announced plans to give GPT-5 a 'warmer personality,' reinstated a retired model, and introduced new options so people can choose how the system responds to their requests. However, one of the biggest hurdles has been limited computing power, which forced OpenAI to prioritize certain users. With 700 million weekly active users and high costs for advanced computing resources, maintaining consistent performance has been a challenge. It also doesn't help that competitors like Anthropic's Claude are becoming more popular with programmers and businesses, while rivals work hard to lure away OpenAI talent and invest heavily in AI research. Nevertheless, although Altman admitted the launch was 'a little more bumpy' than hoped, he said that the team has made breakthroughs despite earlier delays that had some wondering if AI innovation was slowing down. Is MSFT Stock a Buy? Turning to Wall Street, analysts have a Strong Buy consensus rating on MSFT stock based on 34 Buys and one Hold assigned in the last three months. In addition, the average MSFT price target of $623.34 per share implies 18.1% upside potential.
Business Insider
43 minutes ago
- Business Insider
AI Analyst Predicts 50% Upside for HIMS Stock While Wall Street Stays Cautious
While Wall Street analysts remain cautious on Hims & Hers Health (HIMS), TipRanks' A.I. Stock Analysis tool shows strong confidence in the telehealth company's growth. Notably, TipRanks' AI sets a price target of $72 for HIMS stock, implying a 50% upside from current levels, compared with the Wall Street average of $49.11, which indicates only about 2.4% potential growth. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. For context, TipRanks' A.I. Stock Analysis delivers automated, data-driven evaluations of stocks based on key performance metrics, giving investors a clear and concise snapshot of a stock's potential. Notably, HIMS earns a strong score of 74 out of 100 on the tool. AI Analyst Highlights Earnings and Positive Outlook Hims & Hers Health's A.I. score highlights recent Q2 financials and an overall positive outlook. The earnings call showcased solid revenue and subscriber growth, along with expansion into new markets and healthcare services. Notably, Hims & Hers Health saw its subscriber count rise 31% to 2.4 million in Q2. Meanwhile, adjusted EBITDA more than doubled, reaching $82.2 million. On the downside, the company faced challenges, including a drop in GLP‑1 revenue, negative free cash flow, and rising G&A and technology expenses. Specifically, the company's free cash flow took a significant hit, dropping to a negative $69.4 million as of June 30, 2025, compared with a positive $47.6 million a year earlier. The A.I. tool also provides a summary of the company's recent earnings, highlighting both positive and negative updates. A screenshot is shown below for reference. Overall, the A.I. tool sees past the recent short-term volatility. With a growing customer base, new offerings, and market expansion, the current dip could be a buying opportunity for investors focused on the bigger picture. Wall Street Remains Cautious on HIMS Stock After the earnings release, Wall Street remains cautious on HIMS stock. Needham's four-star-rated analyst Ryan MacDonald maintained his Hold rating. He noted that the company's upcoming hormonal health launch and Canadian expansion in 2026 offer growth potential. However, he is concerned that the near-term performance is still heavily tied to weight-loss products, which face regulatory uncertainty. Meanwhile, BofA's top-rated analyst Allen Lutz maintained his Sell rating on HIMS at a price target of $28, predicting a downside of over 40%. Lutz stated that the company is dealing with several short-term challenges, including slow growth in its core business, which could put additional pressure on the GLP-1 segment. He believes that the second half of the year may be even tougher, and near-term cash flow is expected to remain limited as investments continue. Is HIMS Stock a Good Buy? Overall, Wall Street analysts have a Hold consensus rating on HIMS stock based on two Buys, seven Holds, and two Sells assigned in the last three months. The average HIMS stock price target of $49.11 implies an upside of 2.4% from the current trading level.
Business Insider
43 minutes ago
- Business Insider
'San Francisco…Facing the Worst of It' Starbucks Stock (NASDAQ:SBUX) Notches Up as San Francisco Oddly Targeted in Closures
Remember that episode of The Simpsons where Bart gets an earring, and the mall in which he gets it ultimately becomes nothing but Starbucks locations? That is a path coffee giant Starbucks (SBUX) seems eager to change, as it has been closing a lot of stores of late. We just heard yesterday about plans to stop building a community store, and several other stores have followed suit. A recent report suggests that one place hit unusually hard by Starbucks closures is San Francisco. The news did not really shock investors, though, as they gave shares a fractional boost in Wednesday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Reports describe how, in San Francisco, the Starbucks at 295 California Street shut down. This location had been in place for around two decades, reports noted, and was considered a 'fixture' of the San Francisco Financial District. But given that San Francisco has seen a lot of office space go empty of late, that may have sent the demand for carry-out coffee into open decline as well. Though another report suggests that the news may not be so dire. Starbucks itself noted that the California Street closure '…coincided with the natural end of the lease.' Further, Starbucks employees at that location were offered transfers to other stores in the area, so at least there were no layoffs as the result of that location's closure. Yet oddly enough, reports note that there have been four Starbucks locations in San Francisco that were closed just in 2025. Stretch the time scale back to November 2024, and the number rises to six. The Starbucks Job Whether you got the idea from the 2004 movie The Ladykillers, from the 1969 episode of Gomer Pyle, USMC 'Dynamite Diner,' or from somewhere else altogether, you understand the idea of using a nearby location as cover to tunnel into a second location to rob it. Apparently, someone in Kingston, Washington thought this was an excellent idea to put into practice in real life…but targeted a Starbucks location to do it. Kitsap County Sheriff's deputies discovered a 'huge hole burrowed through the wall of the Starbucks,' which originated from a vacant store next to the Starbucks location. What exactly the suspected thieves got from the robbery is unclear, but reports noted they '…went through cash drawers, cut computer cables, went through cabinets, and damaged a safe.' Is Starbucks Stock a Good Buy? Turning to Wall Street, analysts have a Moderate Buy consensus rating on SBUX stock based on 14 Buys, nine Holds and two Sells assigned in the past three months, as indicated by the graphic below. After a 0.56% loss in its share price over the past year, the average SBUX price target of $100.61 per share implies 6.79% upside potential.
